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Abstract We have previously reported that concanavalin A 
(ConA)-induced MMP-2 activation involves both transcriptional 
and non-transcriptional mechanisms. Here we examined the 
effects of calcium influx on MT1-MMP expression and MMP-2 
activation in MDA-MB-231 cells. The calcium ionophore 
ionomycin caused a dose-dependent inhibition of ConA-induced 
MMP-2 activation, but had no effect on MT1-MMP mRNA 
levels. However, Western analysis revealed an accumulation of 
pro-MTl-MMP (63 kDa), indicating that ionomycin blocked the 
conversion of pro-MTl-MMP protein to the active 60 kDa form. 
This suggests that increased calcium levels inhibit the processing 
of MT1-MMP. This finding may help to elucidate the 
mechanism(s) which regulates MT1-MMP activation. 
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1. Introduction 
Members of the matrix metalloproteinase (MMP) enzyme 
family have been broadly implicated in both physiological and 
pathophysiological tissue remodeling [1], and are generally 
secreted as latent zymogens requiring specific activation for 
catalytic activity [2]. MMP-2, also called 72 kDa type IV 
collagenase or gelatinase A, shows specificity for the helical 
regions of collagen type IV, and has been implicated in base-
ment membrane invasion and metastasis of carcinomas [3]. 
Activation of the MMP-2 proenzyme is mediated at the cell 
surface by a subfamily of membrane-associated MMPs 
(MT-MMP), identified recently by PCR homology screening 
(reviewed in [4]). MT1-MMP is co-expressed with MMP-2 in 
embryonic mesenchyme [5] and is dramatically upregulated in 
the stroma surrounding various carcinomas [6-11]. It is also 
up-regulated in gliomas [12], and in the tumor cells of cervical 
[13] and lung [8,14] carcinomas. Furthermore, human breast 
[9,15] and cervical [16] carcinoma cell lines expressing MT1-
MMP show enhanced invasive and metastatic tendencies. Col-
lectively, these data suggest that MT1-MMP, and its activa-
tion of MMP-2, are important in both the local expansion 
and distant metastasis of carcinomatous tumors. Further 
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understanding of the regulation and mechanism of MT1-
MMP-mediated MMP-2 activation may ultimately provide 
new avenues for cancer diagnosis and therapy. 
Despite constitutive expression of MT1-MMP mRNA and 
protein, MMP-2 activation by MDA-MB-231 human breast 
cancer cells requires additional stimulation, and is subject to 
complex regulation [17]. MMP-2 activation by these cells can 
be potently induced by concanavalin A (ConA), which stim-
ulates the steady state levels of MT1-MMP mRNA and pro-
tein, and also mediates some non-transcriptional events which 
appear crucial for MT1-MMP functionality [17]. Calcium is a 
well-known intracellular second messenger which mediates a 
wide range of cellular responses [18,19]. It is required for 
metalloproteinases activity [20] and calcium influx has been 
implicated in TGF-P-induced MMP-2 expression [21]. How-
ever, increased calcium inhibits ConA-, TNFoc- and PMA-
induced MMP-2 activation [22]. In this paper, we examined 
the effect of calcium influx on ConA-induced MT1-MMP 
functionality in MDA-MB-231 cells. Our results suggest that 
calcium influx blocks the constitutive processing of MT1-
MMP without affecting the steady-state mRNA levels. It is 
known that MT1-MMP is constitutively processed into the 
active form by all cells so far studied [12,14,15,23], however 
the mechanism for such activation is not yet clear. Our ob-
servation here that MT1-MMP processing is sensitive to cal-
cium influx may help in the elucidation of this mechanism. 
2. Materials and methods 
2.1. Cells and chemicals 
The MDA-MB-231 cell line was originally obtained from ATCC 
(Rockville, MD) and provided by the Lombardi Cancer Center (LCC) 
Cell Culture Shared Resource. Cells were cultured in IMEM/FCS 
[Richter's IMEM (Biofluids, Rockville, MD) supplemented with 
10% FCS (Gibco, Gaithersburg, MD)] in a 95% air, 5% C02 atmos-
phere at 37°C. Cells were confirmed as mycoplasma-free by the LCC 
Cell Culture Shared Resource using the Genprobe kit (Gen-Probe, 
San Diego, CA) and maintained by weekly passage. Concanavalin 
A (tissue culture grade) and ionomycin were purchased from Sigma 
(St. Louis, MO). Anti-MTl-MMP monoclonal antibody 114-1F2 was 
kindly provided by Dr. K. Iwata, Fuji Chemical Industries, Ltd., 
Takaoka, Japan). Lysates from MTl-MMP-transfected COS-1 cells 
were prepared as previously described [14] and employed as controls 
for Western analysis. 
2.2. Treatment of cells with ConA, and ionomycin 
MDA-MB-231 cells were plated (1 X 105 cells/0.5 ml IMEM/FCS) in 
Costar 24-well clusters, incubated overnight, and then washed in un-
supplemented IMEM twice before treatment and further incubation in 
MMP-2 supplemented serum free medium (MMP-2/SFM) as previ-
ously described [17]. SFM was prepared by supplementing phenol red-
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free Richter's IMEM (Biofluids, Rockville, MD) with glutamine, so-
dium pyruvate, HEPES, vitamins, trace elements and buffered non-
essential amino acids (100 X stock, Biofluids), human plasma fibronec-
tin (1 mg/500 ml) and ITS supplement (2 ml/500 ml, Becton Dickin-
son, Bedford, MA). SFM was then mixed in a ratio of 3:1 with SFM 
conditioned by MMP-2-transfected MCF-7 cells for 24 h. This 
MMP-2/SFM formulation provides a reproducible source of latent 
MMP-2 for activation analysis [9,15,17]. Activation was induced 
with ConA (20 ug/ml) in MMP-2/SFM, in the presence or absence 
of various concentrations of ionomycin. After incubation, conditioned 
media was frozen at —20°C until testing for the activation of the 
exogenous MMP-2 by gelatin zymography. 
2.3. Gelatin zymography 
10% Sodium dodecyl sulfate-polyacrylamide gels copolymerized 
with 2 mg/ml gelatin were used for electrophoresis to resolve latent 
and activated species of MMP-2 as previously described [17]. Bands 
were quantified by densitometry analysis using a Model DNA 35/ 
Sparc Station 2 (pdi NY, NY). 
2.4. Slot-blot analysis of MT1-MMP RNA levels 
Slot-blot analysis was used because we showed previously that our 
MT1-MMP probe recognized only one band on Northern analysis of 
these cells [17]. Cells were plated in 10 cm dishes and treated as 
described above except for the omission of exogenous MMP-2 from 
the incubation media. Total RNA was prepared from cells using ei-
ther 4 M guanidinium thiocyanate and phenol-chloroform or an RNA 
purification kit (Qiagen). For slot-blot analysis, 10 itg total RNA was 
loaded onto nitrocellulose filters in a Minifold II slot-blot apparatus 
(Schleicher and Schuell Inc., Keene, NH). The filter was then pre-
hybridized for 1 h in 50% formamide at 42°C and then hybridized 
overnight at 42°C with a random prime-labeled 32P-MT-MMP cDNA 
PCR fragment probe encompassing bases 98 to 541 [17]. Filters were 
washed with 0.1 XSSC and 1% SDS at 65°C and the bands visualized 
and quantified by phosphorimaging as well as autoradiography. MT1-
MMP mRNA levels were normalized by densitometry of the methyl-
ene blue-stained blot before probing. 
2.5. Western analysis of MT1-MMP protein levels 
Replicate cultures in 10 cm dishes were plated and treated as de-
scribed above for slot-blot analysis. Monolayers were rinsed with Tris-
buffered saline (TBS: 10 mM Tris-HCl, pH 7.5, 150 mM NaCl), 
scraped in ice-cold TBS (1 ml/plate), and sonicated on ice (20 s, 
maximal setting, Microson Ultrasonic Cell Disrupter, Heat Systems 
Ultrasonics Inc., Farmingdale, NY) in the presence of protease inhib-
itors (1 uM PMSF; 0.1 uM aprotinin, 1 itM leupeptin, 1 mM EDTA, 
1 itM pepstatin (Boehringer Mannheim Co., Indianapolis, IN). Ex-
tracts were dissolved in 200 ul 6 X reducing SDS-PAGE sample buffer, 
electrophoresed (20 ill/lane) on 12% SDS-PAGE mini-gels, proteins 
transblotted to a nitrocellulose filter (Amersham) in a Hoeffer Trans-
fer Cell (Hoeffer, Scientific Instruments, San Francisco, CA), and 
blotted with anti-MT-MMP monoclonal antibody 114-1F2 as previ-
ously described [14,17]. Bands were visualized by enhanced chemilu-
minescence (ECL kit, Amersham). 
3. Results and discussion 
Like most invasive human breast cancer cell lines, M D A -
MB-231 cells do not express MMP-2 , but can be induced to 
activate exogenous M M P - 2 when treated with certain stimuli, 
including 3-dimensional fibrillar collagen gels, the phorbol 
ester TPA, and the plant lectin ConA [9,15,24,25]. Among 
these agents, ConA provides the most rapid induction [26], 
which is mediated by a rapid non-transcriptional effect requir-
ing the continued presence of ConA, as well as a slower in-
crease in M T 1 - M M P m R N A levels [17]. In the course of 
screening inhibitors of various signal transduction pathways 
to characterize mechanisms of M T 1 - M M P regulation, we 
found that ionomycin (100 nM), a calcium ionophore, com-
pletely blocked MMP-2 activation induced by ConA treat-
ment of MDA-MB-231 cells. Fig. 1 shows the activation of 
M M P - 2 induced by ConA treatment (lanes 1, 2), and the 
dose-dependent inhibition of this activation by ionomycin 
(lanes 2, 4, 6, 8). ConA-induced MMP-2 activation was com-
pletely inhibited by 100 n M ionomycin (lane 4), while 10 n M 
(lane 6) and 1 n M (lane 8) ionomycin showed no inhibition. 
Ionomycin did not influence the status of the latent MMP-2 
seen in the absence of ConA (lanes 1, 3, 5, 7). 
Because we have found that M T 1 - M M P expression corre-
lates best with both collagen-induced [9] and ConA-induced 
[15] MMP-2 activation in human breast cancer cells, we fur-
ther examined the effect of ionomycin on M T 1 - M M P expres-
sion. M T 1 - M M P m R N A levels were examined by slot blot 
analysis (Fig. 2A) and normalized against methylene blue 
staining of the filter (not shown). Fig. 2B shows the normal-
ized M T 1 - M M P m R N A levels from each of these treatments 
as indicated in the figure. The M T 1 - M M P m R N A level from 
control and ConA treated MDA-MB-231 cells, shown in Fig. 
2B, are consistent with the pattern of the M T 1 - M M P m R N A 
expression levels observed in our previous studies [15,17]. 
When the cells were treated in the combination of ConA 
and ionomycin, the M T 1 - M M P R N A level remains the 
same as that from C o n A treated cells. Ionomycin showed 
no effect on ConA-induced M T 1 - M M P m R N A expression. 
These data suggested that ionomycin may inhibit the non-
Ionomycin nM 
ConA 20 ^g/ml 
1(H) 100 
+ 
10 10 
+ 
1 
+ 
72kDa 
62kl)a 
1 8 
Fig. 1. Zymographic analysis of the effect of the calcium ionophore, ionomycin, on ConA-induced MMP-2 activation. Cells were plated over-
night in 24 well plastic dishes in FCS/IMEM SFM, and treated with MMP-2/SFM only (lane 1), 20 ug/ml ConA (lane 2), 100 ng ionomycin 
(lane 3), 100 ng/ml ionomycin plus 20 ug/ml ConA (lane 4), 10 nM ionomycin (lane 5), 10 nM ionomycin plus 20 itg/ml ConA (lane 6), 1 nM 
ionomycin (lane 7), or 1 nM ionomycin plus 20 ug/ml ConA (lane 8) for 24 h. 
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Fig. 2. Lack of effect of ionomycin ConA-induced increase in MTl-MMP mRNA levels. Cells were plated overnight on 10% FCS/IMEM, into 
10 cm diameter plastic dishes and then incubated in SFM with the indicated concentrations of ionomycin in the presence (gray bar) or absence 
(dark bar) of 20 ug/ml ConA. Total RNA was isolated 24 h after addition of the indicated agents. Ten ug of total RNA from each sample 
were loaded onto nylon membranes in the slot blot apparatus, and probed as described in Section 2. MTl-MMP mRNA levels in slot-blots 
shown in (A). The MTl-MMP signals were quantified by phosphorimaging and normalized by the density of methylene blue staining of the to-
tal RNA on the membrane. The results are expressed as the ratio of MTl-MMP to total RNA loaded on the membrane as shown in (B). 
transcriptional component of ConA regulation that we have 
described previously [17]. 
We further examined MTl-MMP protein profiles by West-
ern blotting (Fig. 3). As described previously [15], there were 
two bands specifically recognized by anti-MTl-MMP mono-
clonal antibodies from ConA-treated cells lysates (lane 3). The 
slower migrating band of approximately 63 kDa co-migrated 
with the major species present in lysates from MT1-MMP-
transfected Cos-1 cells (lane 1). This band has been previously 
identified as pro-MTl-MMP by N-terminal sequencing [14]. 
The faster migrating band is about 10 kDa smaller (about 
50-55 kDa), and its appearance correlated with MMP-2 acti-
vation potential and thus it appears to represent mature MTl-
MMP. This observation is consistent with the previously iso-
lated and N-terminal sequenced native mature MTl-MMP 
protein from TPA-stimulated HT-1080 cells [27]. MTl-
MMP from ConA treated MDA-MB-231 cells occurs pre-
dominantly as the faster migrating band. This pattern has 
also been reported for ConA- or TPA-treated CCL-137 hu-
man lung fibroblasts [28], and is also consistent with other 
reports [23,29]. When MDA-MB-231 cells were treated with 
100 nM ionomycin together with ConA, a dramatic increase 
in the slower-migrating pro-MTl-MMP protein band was de-
tected together with a loss of the faster migrating band (lane 
5), indicating that cellular processing of MTl-MMP is 
blocked. This inhibitory effect was also ionomycin dose-de-
pendent and corresponded to the concentration of ionomycin 
required for inhibition of MMP-2 activation (Fig. 1). Interest-
ingly, ionomycin also appeared to block processing of MTl-
MMP in unstimulated cells. Although sometimes low levels of 
MTl-MMP protein are detected in MDA-MB-231 cell lysates 
under the basal conditions [15], they are close to the level of 
sensitivity limit of the Western analysis. In this experiment, 
MTl-MMP protein was undetectable in control cells (lane 2). 
However, treatment with ionomycin alone resulted in a pro-
nounced band corresponding to pro-MTl-MMP (lane 4), 
again indicating a block in the cellular processing of MTl-
MMP. This data further suggests that ionomycin prevents 
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Fig. 3. Western analysis of the effect of ionomycin on ConA-induced MTl-MMP protein levels. Cells cultured in duplicate dishes were treated 
as described in the legend to Fig. 1. Cell lysates were electrophoresed, transferred to nitrocellulose membranes, and blotted with 114-1F2 anti-
MT1-MMP monoclonal antibody. Lanes: 1, MTl-MMP cDNA transfected Cosl cell lysate; 2, untreated MDA-MB-231 cells; 3, cells treated 
with 20 ug/ml ConA; 4, cells treated with 100 nM ionomycin; 5, cells treated with 100 nM ionomycin plus 20 ug/ml ConA; 6, cells treated 
with 10 nM Ionomycin plus 20 ug/ml ConA; 7, cells treated with 1 ng/ml Ionomycin plus 20 ug/ml ConA. 
constitutive cellular processing of MTl-MMP, rather than 
interfering with ConA-induced regulation. 
It is also possible, however, that the increased cellular cal-
cium blocks the intracellular transport of the MTl-MMP, and 
thus prevent it from reaching its activator molecule. Initial 
reports consistent with the MTl-MMP activation being medi-
ated by furin enzymes in the Golgi apparatus [23] have been 
challenged recently by observations with wild-type pro-MTl-
MMP transfection studies [30], and the precise mechanism 
and localization of the MTl-MMP activator is not yet known. 
However, recombinant forms of MTl-MMP appear to remain 
predominantly latent in the intracellular environment com-
pared to the predominantly active secreted form [23,30], lead-
ing to speculation that activation may be mediated by a plas-
ma membrane-associated entity. 
Lohi et al. have reported that 500 nM ionomycin inhibited 
ConA-, PMA- and TNFa-induced MMP-2 activation in 
HT1080 fibrosarcoma cells [22], broadening the scope of this 
observation to diverse cell types. Ionomycin treatment inhibits 
Con A-treated MDA-MB-231 cells from processing MTl-
MMP protein and resulting MMP-2 activation without affect-
ing ConA-induced increases in MTl-MMP mRNA levels. 
These data confirm that MTl-MMP expression and MMP-2 
activation are sequentially regulated and that post translation-
al modification of MTl-MMP is required for its function. 
Increased calcium levels may be involved in the control of 
MTl-MMP protein processing and hence the activity of 
MTl-MMP. This may be a direct effect, since furin enzymes 
which have been implicated in MT-MMP activation are cal-
cium dependent (reviewed in [31]), as are other MMP's which 
are involved in cross-activation of other family members, and 
could also participate in MTl-MMP activation (reviewed in 
[1]). Plasmin, which is also capable of pro-MTl-MMP proc-
essing [32], is not calcium-dependent. The calcium effects may 
also be indirect, since altered intracellular calcium levels pro-
foundly effect a plethora of cellular pathways. For example, 
calcium/calmodulin-dependent kinases and phosphatases 
could influence factors which directly mediate or regulate 
MTl-MMP trafficking and/or processing. In this light, it is 
interesting to note that the cycling of furin between the plas-
ma membrane and Golgi apparatus is dependent on serine 
and tyrosine residues in the furin cytoplasmic tail [33]. Our 
data, indicating that the localization and/or activation of 
MTl-MMP is sensitive to increased calcium levels, may pro-
vide some clues for the elucidation of this pivotal process. 
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